About eTheRNA immunotherapies

eTheRNA immunotherapies is driving mRNA technology and product development via partnerships and collaboration to deliver an innovative generation of RNA chemistries, breakthrough RNA process technology and a new generation of therapeutic and vaccine products. eTheRNA uses its R&D expertise and in-house GMP manufacturing facilities to build on its proprietary mRNA, mRNA adjuvant and mRNA delivery technology platforms to progress technology innovation and product development. 

eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology. eTheRNA is a private biotechnology company consisting of over 70 employees. The company is headquartered in Niel, Belgium and its subsidiary offices are located in Ghent, Belgium and Sheung Wan, Hong Kong.